Joy M. Schmitz

Joy M. Schmitz

Auto-generated profile, based on publicly available information

Joy M. Schmitz

University of Texas Health Science Center at Houston

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2001 in American Journal of Psychiatry
Verified
Journal Article
Closed access
FMF. Gerard Moeller
F. Gerard Moeller
EBErnest S. Barratt
Ernest S. Barratt
DDDonald M. Dougherty
Donald M. Dougherty
JSJoy M. Schmitz
Joy M. Schmitz
ASAlan C. Swann
Alan C. Swann

1 December 2001 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
FMF.GErard Moeller
F.GErard Moeller
DDDonald M. Dougherty
Donald M. Dougherty
EBErnest S. Barratt
Ernest S. Barratt
JSJoy M. Schmitz
Joy M. Schmitz
ASAlan C. Swann
Alan C. Swann
JGJohn Grabowski
John Grabowski

1 October 2001 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
JGJohn Grabowski
John Grabowski
HRHoward Rhoades
Howard Rhoades
JSJoy Schmitz
Joy Schmitz
ASAngela Stotts
Angela Stotts
LDLee Ann Daruzska
Lee Ann Daruzska
FMF. Gerard Moeller
F. Gerard Moeller
A properly implemented agonist treatment regimen should improve retention and reduce illicit drug use. Cocaine-dependent subjects (N = 128) were enrolled in a 12-week randomized, double-blind, placebo-controlled trial. In the multistage dosing design, subjects initially received placebo (PBO) or 15 to 30 mg of dextroamphetamine sulfate, sustained-release capsules. At week 5, the dose doubled to 30 mg or 60 mg for active groups. Subjects attended the clinic twice a week, provided urine samples, obtained medication, and had one behavioral therapy session a week. Retention was best for the 15-to 30-mg group, whereas the proportion of benzoylecgonine-positive urine screens was, from lowest to highest, 30 to 60 mg, 15 to 30 mg, and PBO at study end. Dosing must be refined. The results provide support for additional examination of the agonist model in psychostimulantdependence treatment.

31 December 2003 in Neuropsychopharmacology
Verified
Journal Article
Closed access
JGJohn Grabowski
John Grabowski
HRHoward Rhoades
Howard Rhoades
ASAngela Stotts
Angela Stotts
KCKatherine Cowan
Katherine Cowan
CKCharles Kopecky
Charles Kopecky
JSJoy Schmitz
Joy Schmitz

1 December 1997 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
JGJohn Grabowski
John Grabowski
JRJohn D. Roache
John D. Roache
JSJoy M. Schmitz
Joy M. Schmitz
HRHoward Rhoades
Howard Rhoades
DCDaniel Creson
Daniel Creson
AKAnia Korszun
Ania Korszun
Agonists, or "replacement medications," are useful adjuncts in treatment of opiate and nicotine dependence. They have not been systematically examined in cocaine dependence. Results of early open trials with methylphenidate for treatment of cocaine dependence were equivocal. Twenty-four cocaine-dependent subjects were enrolled in an 11-week double-blind, placebo-controlled study of methylphenidate. Assignment was random. Intake included a 2-day human laboratory procedure in which subjects received initial doses of methylphenidate or placebo. Subjects attended the clinic Monday through Friday and received oral doses of methylphenidate (5 mg plus 20-mg sustained release) or placebo at 8:00 a.m., with afternoon and weekend take-home doses (20 mg sustained-release or placebo) provided in Medication Events Monitoring System bottles to monitor compliance. Clinic visits included therapy sessions, electrocardiograms, self-report measures, and twice-weekly urine screens. The two groups were equivalent in terms of retention (methylphenidate 48% and placebo 42%) and had similar cocaine use outcomes (40% benzoylecgonine-positive urine screens). There were no significant adverse effects. The doses were sufficient to permit detection of psychoactive effects ("stimulant," "more energy") and side effects ("jitteriness," "eating less") without increased "craving." Additional medications with different effects profiles are being studied to further evaluate the replacement model in cocaine dependence.

1 June 1995 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
JGJohn Grabowski
John Grabowski
HRHoward Rhoades
Howard Rhoades
RERonith Elk
Ronith Elk
JSJoy Schmitz
Joy Schmitz
CDChester Davis
Chester Davis
KKKimberly Kirby
Kimberly Kirby
Cocaine dependence has proved difficult to treat, whether occurring alone or in combination with opiate dependence. No medication has been demonstrated to be uniquely effective. Fluoxetine was examined as a candidate in two randomized, double-blind, placebo-controlled trials, one with cocaine-dependent patients (study 1) and the other with patients both cocaine and opiate dependent (study 2). It was selected for known specific action, antidepressant effects, minimum side effects, and data showing reduced cocaine effect and self-administration. Clinic visit frequency requirement, a variable with implications for treatment and cost, was also examined in study 1. A total of 228 patients in study 1 and 21 patients in study 2 completed consent and intake procedures. Patients with serious medical or DSM-III-R diagnoses other than cocaine dependence (study 1) or opiate and cocaine dependence (study 2) were excluded. Study 1 patients were assigned to one of two visit frequency schedules (2 or 5 days/week) and one of three medication doses (0, 20, or 40 mg of fluoxetine/day). Study 2 patients received placebo or 20 mg of fluoxetine and 65 to 80 mg of methadone and attended the clinic 5 days/week. All patients participated in individual therapy sessions. Urine screens were conducted twice weekly. A fluoxetine dose response relationship emerged in study 1 for retention with groups from best to worst being placebo, 20 mg, and 40 mg. Dose effect order was the same for both visit conditions. Cocaine use persisted in all groups. The two visits/week condition was correlated with better retention than the five visits/week condition. A significant interaction emerged between intake urine and visit frequency; patients with benzoylecognine screens at intake used cocaine significantly less in the 5 days/week condition, while exhibiting no reduction in the 2 days/week condition. Patients cocaine positive at intake were better retained with infrequent visits. In study 2, a transient reduction in benzoylecognine-positive drug screens emerged for the fluoxetine group. These complementary studies demonstrate that fluoxetine is ineffective in reducing cocaine use or craving. Study 1 also points to setting conditions modulating treatment outcome.